[HTML][HTML] Fecal metabolomics and potential biomarkers for systemic lupus erythematosus

Q Zhang, X Yin, H Wang, X Wu, X Li, Y Li… - Frontiers in …, 2019 - frontiersin.org
Q Zhang, X Yin, H Wang, X Wu, X Li, Y Li, X Zhang, C Fu, H Li, Y Qiu
Frontiers in Immunology, 2019frontiersin.org
The role of metabolomics in autoimmune diseases has been a rapidly expanding area in
researches over the last decade, while its pathophysiologic impact on systemic lupus
erythematosus (SLE) remains poorly elucidated. In this study, we analyzed the metabolic
profiling of fecal samples from SLE patients and healthy controls based on ultra-high-
performance liquid chromatography equipped with mass spectrometry for exploring the
potential biomarkers of SLE. The results showed that 23 differential metabolites and 5 …
The role of metabolomics in autoimmune diseases has been a rapidly expanding area in researches over the last decade, while its pathophysiologic impact on systemic lupus erythematosus (SLE) remains poorly elucidated. In this study, we analyzed the metabolic profiling of fecal samples from SLE patients and healthy controls based on ultra-high-performance liquid chromatography equipped with mass spectrometry for exploring the potential biomarkers of SLE. The results showed that 23 differential metabolites and 5 perturbed pathways were identified between the two groups, including aminoacyl-tRNA biosynthesis, thiamine metabolism, nitrogen metabolism, tryptophan metabolism, and cyanoamino acid metabolism. In addition, logistic regression and ROC analysis were used to establish a diagnostic model for distinguishing SLE patients from healthy controls. The combined model of fecal PG 27:2 and proline achieved an area under the ROC curve of 0.846, and had a good diagnostic efficacy. In the present study, we analyzed the correlations between fecal metabolic perturbations and SLE pathogenesis. In summary, we firstly illustrate the comprehensive metabolic profiles of feces in SLE patients, suggesting that the fecal metabolites could be used as the potential non-invasive biomarkers for SLE.
Frontiers